Capabilities
Active Pharmaceutical Ingredients
Product
Facilities
Finished Dose Formulations
Product
Facilities
Antimicrobial Solutions
Novel Medicine
Featured Portfolio
Antimicrobial Stewardship Program
Exblifep
Research
Fighting AMR
Fighting AMR
Antimicrobial Stewardships
Company
About us
Careers
Our thoughts
Investor
Contact
Contact
Stockexchanges
Integrated Corporate Governance Report_December 31, 2024
February 19, 2025
Outcome of BM_February 12, 2025
February 12, 2025
Monitoring Agency Report_Q3_December 31, 2024
February 12, 2025
Press Release_Q3_FY 2024-25
February 12, 2025
Statement of Deviation or Variation for Q3 ending_December 31, 2024
February 12, 2025
Prior intimation of Board Meeting_February, 2025
February 6, 2025
Reconciliation of Share Capital_December 31, 2024
January 25, 2025
Corporate Governance Report_December 31, 2024
January 21, 2025
Investor Grievance Report_December 31, 2024
January 21, 2025
Shareholding Pattern_December 31, 2024
January 21, 2025
Certificate under Reg 74(5) of DP Regulation_December 31, 2024
January 13, 2025
Trading Window Closure_December, 2024
December 30, 2024
Intimation under Reg 30_Corporate Guarantee
December 19, 2024
Outcome of BM_November 11, 2024
November 12, 2024
Statement of Deviation Variation for Q1 ending_September 30 2024
November 12, 2024
Report on Related Party Transactions_Sept 30, 2024
November 12, 2024
Previous
1
...
Next
5 / 36